Company Description
RegenLab is a science-driven regenerative medicine company originally founded in Switzerland and now structured under RegenLab USA, our U.S.-based holding entity.
We operate through a fully integrated platform with three manufacturing sites and dedicated R&D and clinical teams based in New Jersey (USA), Paris (France), and Monthey (Switzerland).
Across these sites, we maintain full control of the development and industrialization cycle, including GMP manufacturing, clinical and regulatory affairs, and global IP management.
RegenLab is the holder of over 70 granted patents, covering proprietary blood-processing devices (Platelet Rich Plasma), crosslinked scaffolds, combination products (PRP with Hyaluronic Acid), bone marrow–derived solutions, and bioengineered matrices designed for point-of-care preparation and safe, reproducible use across outpatient and surgical settings.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 200 |
| CEO | Antonino Turzi |
Contact Details
Address: 95 Greene Street Jersey City, NJ 07302 United States | |
| Phone | 1 (800) 220–9082 |
| Website | regenlabusa.com |
Stock Details
| Ticker Symbol | RGNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2084031 |
| Employer ID | 39-3597532 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Antonino Turzi | Executive Chairman and Chief Executive Officer |
| Jean-Marc Biscarrat | Chief Financial Officer and Director |
| Dr. Giuseppe Calloni, PhD | CEO of RegenLab USA LLC |
| Dr. Daphne Metzger | Chief Operating Officer |
| Eric Del Cotto | Independent Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 25, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 16, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 14, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jan 30, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Oct 20, 2025 | DRS | [Cover] Draft Registration Statement |